YTX 9184
Alternative Names: YTX-9184Latest Information Update: 21 Dec 2022
At a glance
- Originator Yumanity Therapeutics
- Developer Kineta
- Class Antidementias; Antineoplastics; Neuroprotectants; Small molecules
- Mechanism of Action Stearoyl-CoA desaturase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lewy body disease; Solid tumours